<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091012</url>
  </required_header>
  <id_info>
    <org_study_id>DOM-SIL-2009</org_study_id>
    <secondary_id>2009-012005-19</secondary_id>
    <nct_id>NCT01091012</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension</brief_title>
  <official_title>Study About Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension, at Last Moderate and Secondary at Valve Disease(Corrected With a Normally Functioning Prosthesis).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to validate the safety and efficacy of intravenous and oral sildenafil
      in the acute vasodilator test in patients with persistence of, at least, moderate pulmonary
      hypertension after valvular surgery successfully, with a correct left ventricular function
      and no valvular disease hemodynamically significant.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>one day per patient</time_frame>
    <description>The main efficacy parameter is the effect on pulmonary vascular vasodilation quantified as decreased Pulmonary Vascular Resistance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Sildenafil 20mg oral</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil 10mg intravenous</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil 20mg oral vs Sildenafil 10mg intravenous</intervention_name>
    <description>2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg</description>
    <arm_group_label>Sildenafil 20mg oral</arm_group_label>
    <arm_group_label>Sildenafil 10mg intravenous</arm_group_label>
    <other_name>REVATIO oral vs REVATIO intravenous</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients clinically stable, at least 1 year after the completion of successful valve
             surgery, with persistent pulmonary artery systolic pressure&gt; 50 mmHg,

          -  normal left ventricular function and no significant valvular disease in 2 separate
             Doppler ultrasound studies at least 1 month.

        Exclusion Criteria:

          -  Patients with other cardiac and noncardiac diseases will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enric Domingo, Promotor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall Hebron Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enric Domingo, Promotor</last_name>
    <phone>00-34-93-2746455</phone>
    <email>edrcg@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vall Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enric Domingo, Physician</last_name>
      <phone>00-34-93-2746455</phone>
      <email>edrcg@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Enric Domingo, Physician</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Roman, Physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rio Aguilar, Physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Bravo, Physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gisela Teixidor, Physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josep Guindo, Physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Arredondo, Physician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2010</study_first_posted>
  <last_update_submitted>September 10, 2012</last_update_submitted>
  <last_update_submitted_qc>September 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Vasodilator Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

